Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known coronary artery disease~* On maintenance treatment with aspirin (81 mg per day) and clopidogrel (75 mg per day) for at least 1-month as per standard of care.~* Age between 18 and 74 years old.~Exclusion Criteria:~* History of stroke, transient ischemic attack or intracranial bleeding.~* Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel.~* Weight \<60kg~* On treatment with oral anticoagulation (coumarin derivate, dabigatran).~* Hemoglobin\<10 gm/dL~* Platelet count \<80x106/mL~* Active bleeding or hemodynamic instability.~* Creatinine Clearance \<30 mL/minute.~* Baseline ALT \>2.5 times the upper limit of normal.~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~* Drugs interfering with 2C19 metabolism (to avoid interaction with clopidogrel): , fluconazole (Diflucan), ketoconazole (Nizoral), voriconazole (VFEND), etravirine (Intelence), felbamate (Felbatol), fluoxetine (Prozac, Serafem, Symbyax), fluvoxamine (Luvox), and ticlopidine (Ticlid).~* Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant females\*. \*Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel 60mg loading dose and 10 mg maintenance dose
- Ticagrelor (Type: ACTIVE_COMPARATOR): Ticagrelor 180mg loading dose and 90mg bid maintenance dose

Based on this trial design, predict the completion outcome and termination type (if applicable).